𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A medieval case of metastasizing carcinoma with multiple osteosclerotic bone lesions

✍ Scribed by Izabella Tkocz; Franz Bierring


Publisher
John Wiley and Sons
Year
1984
Tongue
English
Weight
608 KB
Volume
65
Category
Article
ISSN
0002-9483

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Multiple myeloma associated with diffuse
✍ Lacy, Martha Q.; Gertz, Morie A.; Hanson, Curtis A.; Inwards, David J.; Kyle, Ro πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 223 KB πŸ‘ 2 views

Multiple myeloma usually is characterized by the development of lytic bone lesions. Osteosclerotic myeloma is a rare entity characterized by a single or multiple osteosclerotic bone lesions and often accompanied by a demyelinating polyneuropathy. Multiple myeloma associated with widespread osteoscle

Pilomatrix carcinoma with multiple visce
✍ Hans P. Niedermeyer; Ketty Peris; Heinz HΓΆfler πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 430 KB πŸ‘ 1 views

## BACKGROUND. The malignant variant of pilomatrixoma is pilomatrix carcinoma, a low-grade, malignant lesion with a tendency to recur. Only three cases with visceral metastases, occurring some years after primary diagnosis, have been reported. METHODS. A case of metastatic pilomatrix carcinoma of

A Phase I study of AMGN-0007, a recombin
✍ Jean-Jacques Body; Philip Greipp; Robert E. Coleman; Thierry Facon; Filip Geurs; πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 107 KB

## Background: Osteoprotegerin (opg) is a decoy receptor for opg ligand (opgl), or receptor activator of nf-kappab ligand (rankl). rankl/rank interaction is important in terminal differentiation and activation of osteoclasts. in binding to rankl, opg blocks differentiation and activation of osteocl

Zoledronic acid is superior to pamidrona
✍ Lee S. Rosen; David H. Gordon; William Dugan Jr.; Pierre Major; Peter D. Eisenbe πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 131 KB πŸ‘ 2 views

## Abstract ## BACKGROUND Treatment with zoledronic acid (Zol) was compared with a dose of 90 mg of pamidronate (Pam) in breast carcinoma (BC) patients with at least 1 osteolytic lesion based on data from a Phase III, randomized trial. ## METHODS Overall, 1130 patients with breast carcinoma who